Semaglutide Research Monograph: Efficacy & Applications
Semaglutide Research Monograph: Efficacy & Applications
Research MonographPublishedpeptideSeptember 9, 202615 References
Route
Subcutaneous injection, Oral
Typical Dose
0.25-2.0 mg weekly (subcutaneous), 3-14 mg daily (oral)
Half-Life
165-184 hours
Stability
Refrigerated storage required for injections
Research Disclaimer: For educational and research purposes only. Not intended as medical advice. Consult qualified healthcare professionals before considering any therapeutic interventions.
CAS Number
910463-68-2
Trade Names
Ozempic, Wegovy, Rybelsus
Development Status
Approved
Primary Targets
GLP1R, Glucagon-like peptide-1 receptor
Summary
This research monograph provides an in-depth analysis of semaglutide, a GLP-1 receptor agonist effective for type 2 diabetes management and weight loss. It discusses its pharmacological mechanisms, clinical applications, safety profile, and emerging evidence highlighting neuroprotective effects. Furthermore, it reviews preclinical and clinical data, pointing towards various ongoing trials and the compound's evolving role in metabolic medicine.